Skip to main content
Clinical Trials/NCT05734820
NCT05734820
Recruiting
Not Applicable

Real-time Computer-aided Polyp/Adenoma Detection During Screening Colonoscopy: a Single-center Crossover Trial

Instituto Ecuatoriano de Enfermedades Digestivas1 site in 1 country312 target enrollmentJanuary 11, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Colorectal Polyp
Sponsor
Instituto Ecuatoriano de Enfermedades Digestivas
Enrollment
312
Locations
1
Primary Endpoint
Adenoma detection rate (ADR)
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

Nowadays, colonoscopy is considered the gold standard for the detection of lesions in the colorectal mucosa. However, around 25% of polyps may be missed during the conventional colonoscopy. Based on this, new technological tools aimed to improve the quality of the procedures, diminishing the technical and operator-related factors associated with the missed lesions. These tools use artificial intelligence (AI), a computer system able to perform human tasks after a previous training process from a large dataset. The DiscoveryTM AI-assisted polyp detector (Pentax Medical, Hoya Group, Tokyo, Japan) is a newly developed detection system based on AI. It was designed to alert and direct the attention to potential mucosal lesions. According to its remarkable features, it may increase the polyp and adenoma detection rates (PDR and ADR, respectively) and decrease the adenoma miss rate (AMR).

Based on the above, the investigators aim to assess the real-world effectiveness of the DiscoveryTM AI-assisted polyp detector system in clinical practice and compare the results between expert (seniors) and non-expert (juniors) endoscopists.

Detailed Description

Colorectal cancer (CRC) is worldwide the second and third cancer-related cause of death in men and women, respectively. For the detection of lesions in the mucosa (premalignant and malignant), colonoscopy has been considered the gold standard. However, up to 25% of lesions can be missed during conventional colonoscopy. Some technical (i.e., bowel preparation) and operator-related (i.e., expertise, and fatigue) factors are related to these missing lesions. During the rapid-growing technological era, new tools were launched to improve the quality and performance of colonoscopies. Through the assistance of artificial intelligence (AI) an identification of a pattern can be achieved after a previous training from a large dataset of images. The DiscoveryTM AI-assisted polyp detector (Pentax Medical, Hoya Group, Tokyo, Japan), is a computer-assisted polyp/adenoma detection system based on AI. It detects classic adenomas and flat lesions, distinguished features like mucus cap or rim of debris with the advantage of a real-time and simultaneous multiple polyp detection. It was developed to minimize the missed lesions increasing as a result the polyp detection rate (PDR) and the adenoma detection rate (ADR). Lately, published data evaluating the AI-assisted polyp detectors has demonstrate high sensitivity, specificity, and interobserver agreement. Due to the importance of CRC diagnosis and prompt treatment, and taking advantage of the newly introduced DiscoveryTM AI system, the investigators aim to assess the real-world effectiveness of this AI-assisted polyp detector system in clinical practice and compare the results between expert (seniors) and non-expert (juniors) endoscopists.

Registry
clinicaltrials.gov
Start Date
January 11, 2020
End Date
September 1, 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
Instituto Ecuatoriano de Enfermedades Digestivas
Responsible Party
Principal Investigator
Principal Investigator

Carlos Robles-Medranda

Head of the Endoscopy Division

Instituto Ecuatoriano de Enfermedades Digestivas

Eligibility Criteria

Inclusion Criteria

  • Adults ≥45 years old
  • Patients referred for screening colonoscopy
  • Adequate bowel preparation, Boston Bowel Preparation Scale (BBPS) ≥8
  • Patients who authorized for endoscopic approach.

Exclusion Criteria

  • Pregnancy
  • Any clinical condition which makes endoscopy inviable.
  • Patients with history of Colorectal Carcinoma.
  • Patients with history of Inflammatory Bowel Disease (IBD)
  • Inability to provide informed consent

Outcomes

Primary Outcomes

Adenoma detection rate (ADR)

Time Frame: up to one month

The ADR will be determined by every new colonoscopy (second intervention) with at least one adenoma, histologically proven/NBI NICE classification. Results will be compared between experts and non-experts endoscopists.

Polyp detection rate (PDR)

Time Frame: up to two hours

The PDR will be determined by every new colonoscopy (second intervention) with at least one polyp. Results will be compared between experts and non-experts endoscopists.

Diagnostic performance of AI-assisted polyp detector

Time Frame: up to three years

The diagnostic performance of the AI-assisted system will be assessed by sensitivity, specificity, positive and negative predictive values (PPV and NPV) and observer agreement.

Secondary Outcomes

  • Adenoma Miss Rate (AMR)(Up to one month)

Study Sites (1)

Loading locations...

Similar Trials